Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence
- PMID: 1539072
- DOI: 10.1016/0091-3057(92)90086-u
Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence
Abstract
Two key strategies for the treatment of drug dependence involve the use of agonists to substitute for the abused drug and the use of antagonists to block the reinforcing actions maintaining drug self-administration. A different strategy for the treatment of drug dependence is outlined, comprising the concurrent administration of an agonist and an antagonist. Concurrent administration of an agonist with an antagonist, in the proper ratio, should produce maximal occupancy of receptors and attenuation of the reinforcing actions of the abused drug. The addict would be relatively "insulated" from the reinforcing effects of the abused drug; at the same time the balance of agonist and antagonist effects is predicted to prevent withdrawal symptoms or intoxication resulting from an under- or over-stimulation of drug receptors. Advantages over the use of agonists alone and antagonists alone, and over mixed agonist-antagonist molecules, are discussed. Application of concurrent agonist-antagonist administration to the analysis of mechanisms underlying nondrug reinforcement and to the treatment of disorders involving receptor disregulation is also described.
Similar articles
-
The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.Psychopharmacology (Berl). 2018 Sep;235(9):2479-2505. doi: 10.1007/s00213-018-4921-9. Epub 2018 Jul 7. Psychopharmacology (Berl). 2018. PMID: 29980822 Review.
-
Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement.Exp Clin Psychopharmacol. 2007 Feb;15(1):1-20. doi: 10.1037/1064-1297.15.1.1. Exp Clin Psychopharmacol. 2007. PMID: 17295581 Review.
-
Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.Addict Behav. 2004 Sep;29(7):1439-64. doi: 10.1016/j.addbeh.2004.06.018. Addict Behav. 2004. PMID: 15345275 Review.
-
Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).Exp Clin Psychopharmacol. 2008 Dec;16(6):475-83. doi: 10.1037/a0014398. Exp Clin Psychopharmacol. 2008. PMID: 19086768 Review.
-
In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.J Pharmacol Exp Ther. 2001 May;297(2):597-605. J Pharmacol Exp Ther. 2001. PMID: 11303048
Cited by
-
Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients.Drug Healthc Patient Saf. 2010 Apr 1;2010(2):39-48. doi: 10.2147/DHPS.S6299. Drug Healthc Patient Saf. 2010. PMID: 21278851 Free PMC article.
-
Potential therapeutic uses of mecamylamine and its stereoisomers.Pharmacol Biochem Behav. 2013 Jul;108:28-43. doi: 10.1016/j.pbb.2013.04.005. Epub 2013 Apr 18. Pharmacol Biochem Behav. 2013. PMID: 23603417 Free PMC article. Review.
-
The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.Psychopharmacology (Berl). 2018 Sep;235(9):2479-2505. doi: 10.1007/s00213-018-4921-9. Epub 2018 Jul 7. Psychopharmacology (Berl). 2018. PMID: 29980822 Review.
-
Nicotine and nonnicotine factors in cigarette addiction.Psychopharmacology (Berl). 2006 Mar;184(3-4):274-85. doi: 10.1007/s00213-005-0250-x. Epub 2005 Dec 16. Psychopharmacology (Berl). 2006. PMID: 16362402 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical